Carisma Therapeutics

Carisma Therapeutics Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Employees
  • 30
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $53M
Latest Deal Amount
  • Investors
  • 11

Carisma Therapeutics General Information

Description

Developer of cell therapies intended to treat solid tumors by re-engineering macrophages. The company's cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment, enabling solid tumor patients to receive strong cellular immunotherapy and cancer treatments.

Contact Information

Formerly Known As
Carma Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Primary Office
  • 3675 Market Street
  • Suite 200
  • Philadelphia, PA 19104
  • United States

Carisma Therapeutics Timeline

2017201820192020
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Carisma Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 08-Aug-2019 $53M 0000 0000 Completed Startup
1. Accelerator/Incubator 31-May-2016 Completed Startup

Carisma Therapeutics Cap Table

To view Carisma Therapeutics‘s complete cap table, request access »
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 000.0 000.0 00 000.0 00.000
Special 0 00.000000

Carisma Therapeutics Competitors (18)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Gadeta Venture Capital-Backed Utrecht, Netherlands 00.000 00000000000 00.000
0000 000000000000 Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
000000000000 Venture Capital-Backed Seattle, WA 00 000.00 00000000000 000.00
00000000 Venture Capital-Backed Tübingen, Germany 000 00000 000000000000 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000

Carisma Therapeutics Executive Team (11)

Name Title Board Seat Contact Info
Steven Kelly President, Chief Executive Officer & Board Member
Daniel Cushing Ph.D Chief Technology and Development Officer
Tom Wilton Chief Business Officer
Michael Klichinsky Co-Founder & Vice President, Discovery Research
Saar Gill MD Co-Founder & Scientific Advisor

Carisma Therapeutics Board Members (11)

To view Carisma Therapeutics‘s full board member team, request access »
Name Representing Role Since
Althea Stillman Ph.D IP Group North America Board Member 000 0000
Bruce Peacock Agent Capital Chairman 000 0000
Eran Nadav Ph.D TPG Biotech Board Member 000 0000
Geeta Vemuri Ph.D Agent Capital Board Observer 000 0000
Hy Levitsky Carisma Therapeutics Board Member 000 0000

Carisma Therapeutics Investors (11)

To view Carisma Therapeutics‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0
Agent Capital Venture Capital Minority 000 0000 000000 0
b-to-v Partners Venture Capital Minority 000 0000 000000 0
Grazia Equity Venture Capital Minority 000 0000 000000 0
HealthCap Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial